ID
45821
Descripción
Principal Investigator: Michael Boehnke, University of Michigan, Ann Arbor, MI, USA MeSH: Diabetes Mellitus, Type 2 https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001048 The Finland-United States Investigation of NIDDM Genetics (FUSION) study is a long-term effort to identify genetic variants that predispose to type 2 diabetes (T2D) or that impact the variability of T2D-related quantitative traits (QTs). Skeletal muscle and adipose are major insulin target tissues and play key roles in insulin resistance. We hypothesize that a subset of T2D and related QT variants alter gene expression in skeletal muscle and adipose tissue. For this FUSION Tissue Biopsy Study, we have obtained and are analyzing RNA-Seq, microRNA (miRNA)-Seq, and DNA methylation (methyl)-Seq data on biopsy samples from 331 individuals from across the range of glucose tolerance: 124 normal glucose tolerance (NGT), 77 impaired glucose tolerance (IGT), 44 impaired fasting glucose (IFG), and 86 newly-diagnosed T2Ds. Participants completed two study visits, two weeks apart. First visits comprised most of the clinical phenotyping, including four-point OGTT (fasting, and 30, 60, and 120 minute post-load); BMI, WHR; lipids; blood pressure; and many other variables. Participants also completed FUSION health history, medication, and lifestyle questionnaires. At second visit, we obtained ~250mg *vastus lateralis* skeletal muscle, ~750mg abdominal subcutaneous adipose, and a ~5x15mm section of abdominal skin. Visits were completed in March 2013. RNA isolation is ongoing in the Collins laboratory at the NIH, RNA and miRNA sequencing at the NIH Intramural Sequencing Center (NISC), and genotyping at the Center for Inherited Disease Research (CIDR). Individual-level data is available here for the 306 individuals who consented to data deposit. To focus on evaluation of gene expression and its regulation in skeletal muscle, we analyzed mRNA extracted from *vastus lateralis* skeletal muscle obtained from 271 of the 331 individual subjects from Finland, along with genome-wide genotypes. Individual-level data is available here for the 250 subjects who reconsented to the use of their data. Release phs001048.v2.p1 adds muscle data for an additional 42 subjects and data from adipose tissue for 276 subjects. Total RNA was isolated using Trizol extraction in the Collins laboratory at the NIH. The mRNA was poly-A selected, 24-plex libraries were generated using the Illumina TruSeq directional mRNA-seq library protocol and RNA sequencing was performed on HiSeq2000 sequencers using 101bp paired-end reads at NISC. miRNA libraries were prepared from total RNA from 296 muscle and 270 adipose samples, pooled and sequenced 50bp single-end reads on Illumina HiSeq2500. Data for 272 muscle and 251 adipose samples are available here for individuals with consent for data deposit. DNA was extracted from blood in the Collins laboratory, and genotyping on the Illumina Omni2.5M array was performed at CIDR. Genotypes were imputed using the HRC 2016 reference panel. In order to assess regions of open chromatin in skeletal muscle, we obtained muscle tissue from a commercial provider to perform ATAC-seq; these samples were sequenced at the University of Michigan DNA Sequencing Core. Greater than 90% of the approximately 80 loci associated with T2D and the 100s of loci associated with T2D-related traits (glucose and insulin, anthropometrics, lipids) through genome-wide association studies occur in non-coding regions, suggesting a strong regulatory component to disease susceptibility. Regulatory element activity is often tissue-specific, which further complicates discovery of the causal/functional variation. Therefore, there is a critical need to understand the full spectrum of genetic variation and regulatory element usage in T2D-relevant tissues. To that end, this study contains whole genome sequence and whole genome bisulfite sequence, and/or Illumina MethylationEPIC Array data, of two tissues relevant to T2D: skeletal muscle and adipose tissue from individuals with glucose tolerance categories ranging from normal to T2D, providing a comprehensive survey of both individual genetic variation as well as DNA methylation across different tissues from multiple individuals.
Link
Palabras clave
Versiones (1)
- 9/7/23 9/7/23 - Simon Heim
Titular de derechos de autor
Michael Boehnke, University of Michigan, Ann Arbor, MI, USA
Subido en
9 de julio de 2023
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs001048 The FUSION Tissue Biopsy Study
This sample attributes table includes body site where sample was collected, analyte type, tumor status, histological type, sample batch (RNA extraction and library creation batch, and sequencing pool), RIN, genotyping and sequencing centers, starting mass of sample, sample use, sample inclusion in analysis, and reason for not including.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent data table contains subject IDs, consent group information, and subject aliases.
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs.
- This subject phenotypes data table includes subject's sex, age at biopsy, OGTT status, fasting plasma glucose and serum insulin, anthropometric measures (n=5 variables; BMI, waist/hip ratio, height, waist circumference, and weight), sample collection site, and smoking status.
- This sample attributes table includes body site where sample was collected, analyte type, tumor status, histological type, sample batch (RNA extraction and library creation batch, and sequencing pool), RIN, genotyping and sequencing centers, starting mass of sample, sample use, sample inclusion in analysis, and reason for not including.
Similar models
This sample attributes table includes body site where sample was collected, analyte type, tumor status, histological type, sample batch (RNA extraction and library creation batch, and sequencing pool), RIN, genotyping and sequencing centers, starting mass of sample, sample use, sample inclusion in analysis, and reason for not including.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent data table contains subject IDs, consent group information, and subject aliases.
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs.
- This subject phenotypes data table includes subject's sex, age at biopsy, OGTT status, fasting plasma glucose and serum insulin, anthropometric measures (n=5 variables; BMI, waist/hip ratio, height, waist circumference, and weight), sample collection site, and smoking status.
- This sample attributes table includes body site where sample was collected, analyte type, tumor status, histological type, sample batch (RNA extraction and library creation batch, and sequencing pool), RIN, genotyping and sequencing centers, starting mass of sample, sample use, sample inclusion in analysis, and reason for not including.
C1299222 (UMLS CUI [1,2])
C0007634 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C2347026 (UMLS CUI [2,1])
C0007634 (UMLS CUI [2,2])
C0449560 (UMLS CUI [2,3])
C1292533 (UMLS CUI [3,1])
C0332307 (UMLS CUI [3,2])
C1292533 (UMLS CUI [4,1])
C0449560 (UMLS CUI [4,2])
C0599776 (UMLS CUI [1,2])
C1294197 (UMLS CUI [1,3])
C5575037 (UMLS CUI [1,2])
C1285573 (UMLS CUI [1,3])
C5575037 (UMLS CUI [1,2])
C1561491 (UMLS CUI [1,3])
C0439659 (UMLS CUI [1,2])
C2347026 (UMLS CUI [1,3])
C1524063 (UMLS CUI [1,4])
C0042153 (UMLS CUI [1,2])
C2347026 (UMLS CUI [1,3])
C0936012 (UMLS CUI [1,2])
C1512698 (UMLS CUI [1,3])
C0445107 (UMLS CUI [1,2])
C0936012 (UMLS CUI [1,3])
Sin comentarios